• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Preoperative treatment with {beta}-blockers is associated with elevated postoperative mortality and cardiac morbidity in patients with uncomplicated hypertension undergoing non-cardiac surgery
Commentary on: Jørgensen ME, Hlatky MA, Køber L, et al.. β-Blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med 2015;175:1923–31. Context The role of β-blockers in preventing cardiovascular complications of non-cardiac surgery is controversial. Early enthusiasm was dampened by accumulating trial data and concerns about the scientific validity of several trials. When studies with uncertain validity are excluded, meta-analyses of randomised trials show that perioperative β-blockers (started within 1 day before surgery) prev...
Source: Evidence-Based Medicine - May 22, 2016 Category: Internal Medicine Authors: Wijeysundera, D. N. Tags: Liver disease, Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Chemotherapy, Ischaemic heart disease Aetiology/Harm Source Type: research